Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany.
Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany; Biomedical Research in End-Stage and Obstructive Lung Disease Hanover (BREATH), Member of the German Center for Lung Research (DZL), Hanover, Germany.
J Heart Lung Transplant. 2016 Jan;35(1):49-58. doi: 10.1016/j.healun.2015.08.016. Epub 2015 Sep 5.
Since April 2010, extracorporeal membrane oxygenation (ECMO) has replaced cardiopulmonary bypass for intraoperative support during lung transplantation at our institution. The aim of this study was to present our 5-year experience with this technique.
Records of patients who underwent transplantation between April 2010 and January 2015 were retrospectively reviewed. Patients who underwent transplantation without ECMO formed Group A. Patients in whom the indication for ECMO support was set a priori before the beginning of the operation formed Group B. The remaining patients in whom the indication for ECMO support was set during transplantation formed Group C.
Among 595 patients, 425 (71%) patients (Group A) did not require intraoperative ECMO; the remaining 170 (29%) patients did. Among these patients, 95 (56%) patients formed Group B, and the remaining 75 (44%) patients comprised Group C. Pulmonary fibrosis and pre-operative dilated or hypertrophied right ventricle emerged as risk factors for the indication of non-a priori intraoperative ECMO. Patients in Groups B and C showed a higher pre-operative risk profile and higher prevalence of post-operative complications than patients in Group A. Overall survival at 1 year was 93%, 83%, and 82% and at 4 years was 73%, 68%, and 69% in Groups A, B, and C (p = 0.11). The intraoperative use of ECMO did not emerge as a risk factor for in-hospital mortality or mortality after hospital discharge.
Intraoperative ECMO filled the gap between pre-operative and post-operative ECMO in lung transplantation. Although complications and in-hospital mortality were higher in patients who received ECMO, survival was similar among patients who underwent transplantation with or without ECMO.
自 2010 年 4 月以来,我院在进行肺移植手术时,已将体外膜肺氧合(ECMO)替代心肺转流用于术中支持。本研究旨在介绍我们应用该技术的 5 年经验。
回顾性分析 2010 年 4 月至 2015 年 1 月期间接受移植的患者记录。未接受 ECMO 支持的患者(A 组)构成患者队列 1;手术前预设 ECMO 支持指征的患者(B 组)构成患者队列 2;术中根据需要设定 ECMO 支持指征的患者(C 组)构成患者队列 3。
595 例患者中,425 例(71%)患者(A 组)不需要术中 ECMO;其余 170 例(29%)患者需要。在这些患者中,95 例(56%)构成 B 组,其余 75 例(44%)构成 C 组。肺纤维化和术前扩张或肥大的右心室是术中预设 ECMO 指征的危险因素。B 组和 C 组患者的术前风险状况和术后并发症发生率均高于 A 组。A、B 和 C 组患者的 1 年总生存率分别为 93%、83%和 82%,4 年总生存率分别为 73%、68%和 69%(p = 0.11)。术中使用 ECMO 不是院内死亡率或出院后死亡率的危险因素。
术中 ECMO 填补了肺移植术前后 ECMO 的空白。尽管接受 ECMO 的患者并发症和院内死亡率较高,但接受 ECMO 或不接受 ECMO 的患者的生存率相似。